[Improvement of hemorheology with ginkgo biloba extract. Decreasing a cardiovascular risk factor].
METHODS
Open prospective study.


METHODS
20 outpatients with a long history of elevated fibrinogen levels and plasma viscosity, and a variety of underlying diseases.


METHODS
Treatment with the special ginkgo biloba extract (EGb 761), 240 mg tablets a day for a period of 12 weeks.


RESULTS
The clinical diagnoses included coronary heart disease, hypertension, hypercholesterolemia and diabetes mellitus. A significant improvement in the fibrinogen levels and hemorrheological properties was seen. The medication can thus positively influence these cardiovascular risk factors over the long term.
Witte
S
S
Medizinische Abteilung, Diakonissen-Krankenhaus Karlsruhe Rüppurr.
Anadere
I
I
Walitza
E
E
D000368:Aged; D001809:Blood Viscosity / Q000187:drug effects*; D002318:Cardiovascular Diseases / Q000097:blood / Q000628:therapy*; D005260:Female; D005340:Fibrinogen / Q000378:metabolism*; D020441:Ginkgo biloba; D006801:Humans; D008297:Male; D008875:Middle Aged; D010936:Plant Extracts / Q000627:therapeutic use*; D011446:Prospective Studies; D012212:Rheology; D012307:Risk Factors; D000096983:Ginkgo Extract
D005340:Fibrinogen; D010936:Plant Extracts; C063170:Ginkgo biloba extract; D000096983:Ginkgo Extract
Verbesserung der Hämorheologie durch Ginkgo-biloba-Extrakt. Verminderung eines kardiovaskulären Risikofaktors.